ADMA Biologics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade ADMA Biologics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ADMA

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. 

CEO
Adam S. Grossman
CEOAdam S. Grossman
Employees
647
Employees647
Headquarters
Ramsey, New Jersey
HeadquartersRamsey, New Jersey
Founded
2004
Founded2004
Employees
647
Employees647

ADMA Key Statistics

Market cap
3.66B
Market cap3.66B
Price-Earnings ratio
26.17
Price-Earnings ratio26.17
Dividend yield
Dividend yield
Average volume
4.53M
Average volume4.53M
High today
$15.57
High today$15.57
Low today
$15.17
Low today$15.17
Open price
$15.34
Open price$15.34
Volume
1.03M
Volume1.03M
52 Week high
$25.67
52 Week high$25.67
52 Week low
$13.76
52 Week low$13.76

Stock Snapshot

ADMA Biologics(ADMA) stock is priced at $15.37, giving the company a market capitalization of 3.66B. It carries a P/E multiple of 26.17.

As of 2026-03-06, ADMA Biologics(ADMA) stock has fluctuated between $15.17 and $15.57. The current price stands at $15.37, placing the stock +1.3% above today's low and -1.3% off the high.

ADMA Biologics(ADMA) shares are trading with a volume of 1.03M, against a daily average of 4.53M.

In the last year, ADMA Biologics(ADMA) shares hit a 52-week high of $25.67 and a 52-week low of $13.76.

In the last year, ADMA Biologics(ADMA) shares hit a 52-week high of $25.67 and a 52-week low of $13.76.

ADMA News

Simply Wall St 18h
ADMA Biologics Buyback Plan Tests Earnings Story And Valuation Gap

ADMA Biologics (NasdaqGM:ADMA) has launched a $200 million capital return program anchored by a $125 million accelerated share repurchase. The company plans to...

ADMA Biologics Buyback Plan Tests Earnings Story And Valuation Gap
Nasdaq 4d
ADMA Biologics Announces $200 Mln Capital Return Plan

(RTTNews) - ADMA Biologics, Inc. (ADMA), a biopharmaceutical company, Monday announced a capital return initiative target of around $200 million including an ac...

ADMA Biologics Announces $200 Mln Capital Return Plan
TipRanks 4d
Adma Biologics announces $125M accelerated share repurchase with JPMorgan

ADMA Biologics (ADMA) announced a capital return initiative target of approximately $200M during 2026, including the execution of a $125M accelerated share repu...

More ADMA News

Simply Wall St 6d
ADMA Biologics Valuation After Revenue Growth Guidance Reaffirmation And CFO Transition

ADMA Biologics (ADMA) shares are in focus after the company paired strong 2025 revenue and earnings with reaffirmed multi year guidance, yield focused operation...

ADMA Biologics Valuation After Revenue Growth Guidance Reaffirmation And CFO Transition
Nasdaq 7d
ADMA Biologics Q4 2025 Earnings Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

ADMA Biologics Q4 2025 Earnings Transcript

People also own

Based on the portfolios of people who own ADMA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.